Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus
bevacizumab as first line treatment in patients with metastatic and HER2 negative breast
cancer.